Literature DB >> 9297733

Stability of nystatin in mouthrinses; effect of pH temperature, concentration and colloidal silver addition, studied using an in vitro antifungal activity.

N Vermerie1, C Malbrunot, M Azar, P Arnaud.   

Abstract

Alkaline low concentration nystatin mouthrinses extemporanely prepared can be used to treat oropharyngeal candidiasis in immunodeficient patients. However, their expiration dates are not distinctly determined. The stability of nystatin, added (as Mycostatine) at a concentration of 14,400 U/ml in 10-4N hydrochloric acid, purified water and 1.4% injectable sodium hydrogen carbonate with or without 0.002% colloidal silver (an antiseptic agent added because of its known antifungal potency) was studied after storage in tinted glass bottles at 5 degrees C and 22 degrees C over 11 days, and compared with reconstituted 100,000 U/ml aqueous Mycostatine oral suspension. At 2, 4, 7, 9, and 11 days after preparation. Samples were tested for pH, microbial contamination, and assayed by an in vitro microbiological test. Neither significant variation of pH nor microbial contamination were in evidence. Nystatin 14400 U/ml maintained at least 90% of its initial concentration for 4 days in acid at both temperatures, for 7 days (5 degrees C) and 4 days (22 degrees C) in aqueous and alkaline environments, for 9 days (5 degrees C) and 7 days (22 degrees C) in 1.4% injectable sodium hydrogen carbonate containing colloidal silver which showed an antifungal potency. The 100,000 U/ml aqueous Mycostatine oral suspension was stable for 9 days and 4 days at 5 degrees C and 22 degrees C respectively. An ambulant patient can keep a low concentration alkaline antifungal mouthrinse at home for a week at 5 degrees C.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9297733     DOI: 10.1023/a:1008664917377

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  7 in total

1.  Electrochemical Ag+ for preservative use.

Authors:  N Simonetti; G Simonetti; F Bougnol; M Scalzo
Journal:  Appl Environ Microbiol       Date:  1992-12       Impact factor: 4.792

2.  Treatment of oral candidiasis with amphotericin B solution.

Authors:  R Brandell; S L Chase; J R Cohn
Journal:  Clin Pharm       Date:  1988-01

3.  Assessment of oral candidiasis in patients with respiratory disease and efficacy of a new nystatin formulation.

Authors:  P J Thompson; H J Wingfield; R F Cosgrove; B O Hughes; M E Turner-Warwick
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-28

4.  The effect of pH and of temperature on the stability and bioactivity of nystatin and amphotericin B.

Authors:  J M Hamilton-Miller
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

Review 5.  Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections.

Authors:  F Meunier-Carpentier
Journal:  Am J Med       Date:  1984-04       Impact factor: 4.965

6.  Treatment and prevention of oropharyngeal candidiasis.

Authors:  R Quintiliani; N J Owens; R A Quercia; J J Klimek; C H Nightingale
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

7.  Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation.

Authors:  J B Epstein; L Vickars; J Spinelli; D Reece
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1992-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.